Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02601313 · ClinicalTrials.gov registry record · Phase 2
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)
A Phase 2 study, sponsored by Kite, A Gilead Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT02601313 is a Phase 2 study that has completed, run by Kite, A Gilead Company. The registered enrollment target is 105 participants.
The verdict
NCT02601313, a Phase 2 study, has completed, sponsored by Kite, A Gilead Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
The goal of this clinical study is to test how well the study drug, brexucabtagene autoleucel (KTE-X19), works in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL).
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Axicabtagene Ciloleucel
- BIOLOGICAL brexucabtagene autoleucel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2015-11-09 |
| Est. Completion | 2023-09-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02601313
The ClinicalTrials.gov registry entry for NCT02601313 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT02601313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02601313 about?
NCT02601313 is a clinical study titled "Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)". The goal of this clinical study is to test how well the study drug, brexucabtagene autoleucel (KTE-X19), works in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL).
What is the current status of trial NCT02601313?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2015-11-09. Estimated completion is 2023-09-22.
What interventions are being tested in trial NCT02601313?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Axicabtagene Ciloleucel (DRUG), brexucabtagene autoleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT02601313?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.